Major Depressive Disorder

1. Topic Overview

Summary

Major Depressive Disorder (MDD) is a common, serious, and potentially life-threatening mood disorder characterised by persistent low mood, anhedonia (loss of pleasure in activities), and a constellation of cognitive, behavioural, somatic, and neurovegetative symptoms. MDD affects approximately 5-7% of adults globally at any given time, with lifetime prevalence of 15-20%, representing a leading cause of disability worldwide and a major contributor to the global burden of disease. [1,2]

The disorder is distinguished from normal sadness or grief by the severity, duration (minimum 2 weeks), and functional impairment of symptoms. MDD exists on a severity spectrum from mild (minimal functional impairment) to severe with psychotic features (profound impairment, life-threatening risk). The condition is highly recurrent, with 50% experiencing a second episode after an initial episode and 80% after two episodes. [3]

Effective treatment is available and essential. Evidence-based interventions include antidepressant pharmacotherapy (SSRIs first-line), psychological therapies (CBT, interpersonal therapy, behavioural activation), and in severe or treatment-resistant cases, electroconvulsive therapy (ECT). Combined pharmacotherapy and psychotherapy produces superior outcomes compared to either modality alone. [4,5] Early recognition, comprehensive suicide risk assessment, and prompt evidence-based treatment significantly improve outcomes and can be life-saving.

Key Facts

Clinical Pearls

High-Yield Examination Points:

• Core Triad: Low mood, Anhedonia, Anergia (lack of energy) — at least one of first two required
• Biological Symptoms indicate severity: early morning wakening (2-3 hours early), diurnal mood variation (worst in morning), psychomotor retardation/agitation, marked weight loss, loss of libido
• Suicide Risk Assessment is mandatory at every encounter — ask directly about ideation, plans, intent, means, protective factors
• SSRIs require 4-6 weeks for therapeutic effect — warn patients to prevent premature discontinuation; some improvement may occur by 2 weeks
• Continuation therapy for 6-12 months after remission (first episode), ≥2 years if recurrent depression
• PHQ-9 scores: 5-9 mild, 10-14 moderate, 15-19 moderately severe, ≥20 severe
• Rule out organic causes: hypothyroidism (TFTs), anaemia (FBC), hypercalcaemia, B12/folate deficiency, medication-induced (beta-blockers, steroids, isotretinoin)
• Combination therapy (antidepressant + psychotherapy) is more effective than either alone for moderate-severe depression
• Treatment-resistant depression defined as failure of ≥2 adequate trials (adequate dose, ≥4-6 weeks duration)

Why This Matters Clinically

Major Depressive Disorder is among the most prevalent conditions encountered across all medical specialties, not just psychiatry. Depression worsens outcomes in cardiovascular disease (2-3× mortality post-MI), diabetes (poorer glycaemic control), cancer (reduced treatment adherence), and chronic pain. [11] It is the most common psychiatric disorder in primary care, presenting in 10-15% of consultations, yet remains underdiagnosed and undertreated.

Untreated or inadequately treated depression leads to:

• Suicide: 15-20% lifetime risk in severe untreated depression [7]
• Reduced life expectancy: 10-20 year reduction from suicide, cardiovascular disease, and other causes
• Profound functional impairment: work disability, relationship breakdown, social isolation
• Chronicity: longer untreated episodes predict worse long-term outcomes

Early detection using validated screening tools (PHQ-9), comprehensive risk assessment, and evidence-based treatment can reverse these trajectories. Depression is eminently treatable — 60-70% respond to first-line treatment, and up to 80-90% achieve remission with sequential or combination strategies. Recognition and intervention save lives.

---

2. Epidemiology

Prevalence and Incidence

Major Depressive Disorder ranks among the most common psychiatric disorders globally and is the leading cause of years lived with disability (YLDs). [1]

Demographic Patterns

Age:

• Peak onset: 20-30 years (median age 32) [6]
• Can occur at any age, including childhood and elderly
• Late-onset depression (>65 years) more often associated with cognitive impairment and vascular changes
• Adolescent-onset predicts more recurrent, severe course

Sex:

• Female:Male ratio approximately 2:1 across all ages [2]
• Difference emerges at puberty (pre-pubertal rates equal)
• Possible mechanisms: hormonal influences, psychosocial stressors, differential help-seeking, reporting bias

Ethnicity and Culture:

• Depression occurs across all cultures and ethnicities
• Presentation may vary (somatisation more common in some cultures)
• Access to care and treatment rates vary significantly

Socioeconomic Factors:

• Inverse relationship with socioeconomic status
• Higher rates in unemployed, homeless, imprisoned populations
• Urban versus rural differences (higher in urban settings in some studies)

Risk Factors

Non-Modifiable Factors:

Modifiable Risk Factors:

Precipitating Factors (Life Events):

• Bereavement and loss (especially complicated grief)
• Relationship breakdown (separation, divorce)
• Serious physical illness diagnosis
• Financial crisis or debt
• Work-related stress or job loss
• Traumatic events
• Postpartum period (10-15% develop postpartum depression) [15]
• Seasonal changes (in seasonal affective disorder variant)

Iatrogenic and Medication-Induced:

• Beta-blockers (especially propranolol, metoprolol)
• Corticosteroids (prednisone, dexamethasone)
• Isotretinoin (acne treatment)
• Interferon (hepatitis C, multiple sclerosis treatment)
• Certain anticonvulsants (topiramate, vigabatrin)
• Goserelin and other hormonal agents

Protective Factors

• Strong social support networks
• Stable employment
• Physical activity and exercise
• Meaningful relationships
• Sense of purpose or spirituality
• Resilience and adaptive coping strategies
• Access to healthcare

---

3. Aetiology and Pathophysiology

Major Depressive Disorder is best understood through a biopsychosocial model integrating biological vulnerabilities, psychological factors, and social/environmental stressors. No single cause is sufficient; rather, the interaction of multiple factors confers risk.

Biological Models

3.1 Monoamine Hypothesis

The classical theory posits that depression results from deficiency of monoamine neurotransmitters (serotonin, norepinephrine, dopamine) in key brain regions. [16]

Evidence Supporting:

• Reserpine (depletes monoamines) induces depressive symptoms
• Antidepressants increase synaptic monoamine availability
• Acute tryptophan depletion (serotonin precursor) can precipitate relapse in vulnerable individuals

Limitations:

• Oversimplified: monoamine depletion does not cause depression in healthy individuals
• Delayed therapeutic effect of antidepressants (weeks) versus immediate monoamine increase (hours)
• 30-40% of patients do not respond to monoaminergic antidepressants

Clinical Relevance:

• Remains the basis for SSRI, SNRI, TCA, and MAOI mechanisms
• Useful framework for understanding medication classes
• Incomplete explanation of pathophysiology

3.2 Neuroplasticity and Neurogenesis Model

Depression is associated with impaired neuroplasticity, reduced neurogenesis, and structural brain changes. [17]

Key Findings:

• Hippocampal volume reduction (5-10% decrease in recurrent MDD)
• Reduced BDNF (brain-derived neurotrophic factor) in depression; increased with antidepressant treatment
• Impaired neurogenesis in hippocampal dentate gyrus
• Synaptic pruning and dendritic atrophy in prefrontal cortex

Mechanism:

• Chronic stress → glucocorticoid excess → hippocampal damage → impaired neurogenesis
• Antidepressants increase BDNF → enhance neuroplasticity → symptom improvement (explains delayed therapeutic effect)

Evidence:

• Animal models: chronic stress induces neurobiological changes reversed by antidepressants
• Human imaging studies: hippocampal volume correlates with episode number and duration
• Post-mortem studies: altered synaptic density in depression

3.3 HPA Axis Dysregulation

The hypothalamic-pituitary-adrenal (HPA) axis is chronically hyperactive in 50-60% of MDD patients. [16]

Normal Stress Response: Stressor → CRH (hypothalamus) → ACTH (pituitary) → Cortisol (adrenal) → Negative feedback

In Depression:

• Chronic stress leads to sustained cortisol elevation
• Impaired negative feedback (glucocorticoid receptor dysfunction)
• Elevated 24-hour urinary free cortisol
• Non-suppression on dexamethasone suppression test (DST) in ~50%

Consequences:

• Hippocampal damage (high density of glucocorticoid receptors)
• Impaired cognition and memory
• Metabolic effects (weight gain, insulin resistance)

Recovery:

• HPA axis normalises with successful treatment
• Persistent HPA dysregulation predicts relapse

3.4 Inflammatory Hypothesis

Emerging evidence implicates chronic low-grade inflammation in the pathophysiology of depression, particularly in treatment-resistant cases. [18]

Evidence:

• Elevated inflammatory markers: IL-6, TNF-α, CRP in 30-50% of MDD patients
• Sickness behaviour induced by cytokines resembles depression (fatigue, anhedonia, social withdrawal, psychomotor slowing)
• Interferon therapy induces depression in 30-50% (model for cytokine-induced depression)
• Anti-inflammatory treatments: NSAIDs, anti-cytokine biologics show antidepressant effects in some studies

Mechanisms:

• Cytokines activate indoleamine 2,3-dioxygenase (IDO) → tryptophan shunted to kynurenine pathway → reduced serotonin synthesis
• Inflammatory activation of microglia in brain
• Oxidative stress and mitochondrial dysfunction

Clinical Implications:

• Subgroup of patients with "inflammatory depression" may benefit from anti-inflammatory approaches
• Comorbid medical conditions (diabetes, cardiovascular disease) share inflammatory pathways

3.5 Genetic and Epigenetic Factors

Heritability:

• Twin studies: 40% heritability (higher for recurrent/severe forms) [13]
• No single "depression gene" — polygenic inheritance with small-effect variants

Candidate Genes:

• Serotonin transporter gene (5-HTTLPR): short allele associated with increased vulnerability to stress
• BDNF gene variants
• Glucocorticoid receptor gene polymorphisms

Gene-Environment Interactions:

• Genetic vulnerability + early life stress → increased risk
• Epigenetic modifications (DNA methylation, histone acetylation) mediate effects of childhood adversity

Psychological Models

3.6 Cognitive Model (Beck)

Aaron Beck's cognitive theory proposes that depression arises from negative cognitive schemas and distorted thinking patterns. [19]

Cognitive Triad of Depression:

1. Negative view of self ("I am worthless")
2. Negative view of world ("Everything is hopeless")
3. Negative view of future ("Nothing will improve")

Cognitive Distortions:

• Overgeneralisation: single negative event viewed as never-ending pattern
• Catastrophising: magnifying negative events
• Personalisation: blaming oneself for external events
• All-or-nothing thinking: viewing situations in black-and-white extremes
• Selective abstraction: focusing only on negative details

Automatic Negative Thoughts:

• Rapid, reflexive negative interpretations of situations
• Not consciously deliberated
• Drive depressive emotions and behaviours

Therapeutic Implication:

• Forms the basis of Cognitive Behavioural Therapy (CBT)
• Identifying and challenging cognitive distortions leads to symptom improvement

3.7 Learned Helplessness (Seligman)

Martin Seligman's model proposes that depression results from learned expectations of uncontrollability. [20]

Animal Model:

• Dogs exposed to inescapable electric shocks later failed to escape even when escape was possible
• Generalised expectation of helplessness developed

Human Application:

• Repeated exposure to uncontrollable negative events → belief that actions cannot influence outcomes
• Attribution style: internal ("it's my fault"), stable ("it will always be this way"), global ("it affects everything")

Therapeutic Implication:

• Behavioural activation helps patients re-learn control and mastery
• Cognitive restructuring addresses attributional style

3.8 Behavioural Model (Lewinsohn)

Depression arises from reduced positive reinforcement from the environment, leading to withdrawal and further reduction in rewarding activities (negative cycle). [21]

Mechanism: Loss of reinforcers (job, relationship, health) → Reduced activity → Fewer rewarding experiences → Increased depression → Further withdrawal

Therapeutic Implication:

• Behavioural Activation (BA): systematically increasing engagement in valued activities
• Breaking the cycle by scheduling pleasurable and mastery-oriented activities

Neuroanatomical Findings

Functional Neuroimaging (fMRI, PET):

• Prefrontal cortex: reduced activity (especially dorsolateral PFC) — impaired executive function, cognitive control
• Anterior cingulate cortex: hyperactivity — increased emotional processing of negative stimuli
• Amygdala: hyperactivity — emotional reactivity, negative bias
• Hippocampus: reduced volume and activity — memory impairment

Network Model:

• Dysregulation of emotion regulation circuits
• Imbalance between cognitive control (PFC) and emotional reactivity (amygdala, anterior cingulate)

---

4. Clinical Presentation

Diagnostic Criteria

Major Depressive Disorder is diagnosed using DSM-5 (Diagnostic and Statistical Manual, 5th Edition) or ICD-11 (International Classification of Diseases, 11th Revision) criteria. Both systems require symptom presence, duration, and functional impairment.

DSM-5 Criteria for Major Depressive Episode

A. Five or more of the following symptoms present during the same 2-week period, representing a change from previous functioning. At least one symptom must be (1) or (2):

Core Symptoms (at least one required):

1. Depressed mood most of the day, nearly every day (subjective report or observed by others)
2. Anhedonia: markedly diminished interest or pleasure in all or almost all activities most of the day, nearly every day

Additional Symptoms: 3. Significant weight loss (when not dieting) or weight gain (>5% body weight in 1 month), or decrease/increase in appetite nearly every day 4. Insomnia or hypersomnia nearly every day 5. Psychomotor agitation or retardation nearly every day (observable by others, not merely subjective) 6. Fatigue or loss of energy nearly every day 7. Feelings of worthlessness or excessive/inappropriate guilt (may be delusional) nearly every day 8. Diminished ability to think or concentrate, or indecisiveness, nearly every day 9. Recurrent thoughts of death (not just fear of dying), recurrent suicidal ideation without specific plan, or suicide attempt or specific plan for suicide

B. Symptoms cause clinically significant distress or impairment in social, occupational, or other important areas of functioning

C. Episode not attributable to physiological effects of substance or medical condition

D. Not better explained by schizophrenia spectrum or other psychotic disorders

E. No history of manic or hypomanic episode (would indicate bipolar disorder instead)

Duration: Symptoms present for ≥2 weeks

Severity Classification (DSM-5)

Specifiers (Important for Treatment Selection)

With Anxious Distress:

• ≥2 of: feeling keyed up/tense, restless, difficulty concentrating due to worry, fear something awful will happen, fear of losing control
• Present in ~70% of MDD; associated with greater severity, suicidality, poorer outcomes
• May require augmentation with anxiolytic strategies

With Melancholic Features (indicates more severe biological depression):

• Loss of pleasure in all activities (complete anhedonia)
• Lack of mood reactivity (mood does not brighten in response to positive events)
• Plus ≥3 of:
  • Distinct quality of depressed mood (different from grief)
  • Depression regularly worse in the early morning
  • Early morning awakening (≥2 hours before usual time)
  • Marked psychomotor retardation or agitation
  • Significant anorexia or weight loss
  • Excessive or inappropriate guilt
• Associated with better response to ECT and tricyclic antidepressants

With Atypical Features:

• Mood reactivity (mood brightens in response to positive events)
• Plus ≥2 of:
  • Significant weight gain or increased appetite ("comfort eating")
  • Hypersomnia (excessive sleep)
  • Leaden paralysis (heavy feeling in arms or legs)
  • Interpersonal rejection sensitivity (not limited to episodes)
• Associated with preferential response to MAOIs (historical); now SSRIs/SNRIs first-line

With Psychotic Features:

• Presence of delusions and/or hallucinations
• Mood-congruent (consistent with depressive themes):
  • "Delusions of guilt, sin, worthlessness, nihilism (Cotard's delusion: belief one is dead)"
  • Delusions of deserved punishment, disease, poverty
  • "Auditory hallucinations: derogatory voices"
• Mood-incongruent (inconsistent with depressive themes): worse prognosis
• Requires antipsychotic + antidepressant OR electroconvulsive therapy

With Catatonia:

• Rare but serious: stupor, mutism, posturing, negativism
• Medical emergency requiring urgent treatment

With Peripartum Onset:

• Onset during pregnancy or within 4 weeks postpartum
• 10-15% of women; higher risk with previous history [15]
• Risk to mother and infant; requires prompt treatment

With Seasonal Pattern (Seasonal Affective Disorder):

• Regular temporal relationship between depressive episodes and time of year (typically autumn/winter)
• Full remission in characteristic times of year (spring/summer)
• Responds to light therapy (10,000 lux for 30 minutes daily)

Biological Symptoms (Somatic Syndrome)

The presence of biological/melancholic symptoms is an important marker of severity and guides treatment selection (more likely to require medication). [22]

Mental State Examination Findings

A systematic Mental State Examination (MSE) documents objective findings and severity.

• "empty"
• "hopeless"
• "black"
• "numb" — patient's description | | Affect (Objective) | Depressed, flattened (reduced range), blunted (reduced intensity); congruent with mood; may be tearful | | Thought Form | Slowed thinking (bradyphrenia); rumination; poverty of thought in severe cases | | Thought Content | Themes of guilt, worthlessness, hopelessness, self-blame; suicidal ideation; delusions (if psychotic) | | Perception | Usually normal; auditory hallucinations if psychotic (derogatory voices) | | Cognition | Impaired concentration and memory; "pseudodementia" in severe/elderly (reversible with treatment) | | Insight | Usually preserved (aware of being unwell); may be impaired in psychotic depression |

Risk Assessment (MANDATORY)

Suicide risk assessment must be performed at every clinical contact. Direct questioning about suicidal thoughts does not increase risk and is essential for safety planning.

Suicide Risk Factors (Mnemonic: SAD PERSONS)

Specific Questions to Ask

Direct Assessment:

1. "Have you had thoughts that life is not worth living?"
2. "Have you had thoughts of harming yourself or ending your life?"
3. If YES: "Have you made any plans about how you would do this?"
4. "Do you have access to [means mentioned]?"
5. "What has stopped you from acting on these thoughts?"
6. "Have you ever attempted to harm yourself or end your life before?"

Protective Factors:

• Reasons for living (children, family, pets, spiritual beliefs)
• Future-oriented thinking
• Therapeutic alliance
• Social support
• No access to lethal means

Immediate Safety:

• High risk (intent + plan + means + no protective factors): psychiatric emergency, consider involuntary admission
• Moderate risk: crisis plan, remove means, frequent follow-up, consider admission
• Low risk: outpatient management, safety plan, crisis contact information

Differential Diagnosis

Depression must be distinguished from other conditions presenting with low mood or overlapping symptoms.

Medical Causes to Exclude (Organic Workup):

• Hypothyroidism (10% of presentations)
• Anaemia (especially B12/folate deficiency)
• Hypercalcaemia
• Cushing's syndrome
• Addison's disease
• Hypogonadism
• Obstructive sleep apnoea
• Neurological conditions (stroke, Parkinson's disease, multiple sclerosis, brain tumour)

---

5. Investigations

The primary purpose of investigations in suspected Major Depressive Disorder is to exclude organic causes and establish baseline parameters before treatment. There is no diagnostic test for depression — diagnosis remains clinical based on history and mental state examination.

Screening and Assessment Tools

PHQ-9 (Patient Health Questionnaire-9) — Gold standard screening tool [23]

• 9 items corresponding to DSM-5 criteria
• Scored 0-27 (each item 0-3 based on frequency)
• Interpretation:
  • 0-4: Minimal/none
  • 5-9: Mild depression
  • 10-14: Moderate depression
  • 15-19: Moderately severe depression
  • ≥20: Severe depression
• Sensitivity 88%, specificity 88% for major depression (score ≥10)
• Item 9 specifically assesses suicidal ideation
• Useful for monitoring treatment response over time

GAD-7 (Generalised Anxiety Disorder-7)

• Often administered alongside PHQ-9
• Assesses comorbid anxiety (present in ~70% of MDD)
• Score ≥10 indicates clinically significant anxiety

Other Scales (Less Commonly Used in Routine Practice):

• HAMD (Hamilton Depression Rating Scale): clinician-rated, 17 or 21 items; used in research
• BDI-II (Beck Depression Inventory): 21-item self-report
• MADRS (Montgomery-Åsberg Depression Rating Scale): clinician-rated, 10 items; sensitive to change

Laboratory Investigations

Purpose: Rule out organic causes, establish baseline before medication

If Clinically Indicated:

• Urine drug screen: if substance use suspected
• Cortisol (9am, midnight salivary, or 24h urine free cortisol): if Cushing's syndrome suspected
• Testosterone (in men): hypogonadism
• HIV, Syphilis serology: if risk factors present
• CT/MRI brain: if neurological signs, focal deficit, new-onset in elderly, treatment-resistant

Baseline Investigations Before Starting Antidepressants

Before SSRI/SNRI:

• FBC, U&Es, LFTs (baseline)
• Consider ECG if cardiovascular risk factors (citalopram prolongs QTc)

Before Mirtazapine:

• FBC (rare risk of bone marrow suppression)
• Weight and BMI (causes weight gain)
• Lipid profile and glucose (metabolic effects)

Before Tricyclic Antidepressants (TCAs):

• ECG (essential — TCAs prolong QTc, risk of arrhythmia)
• U&Es
• Contraindicated if recent MI, heart block, QTc >450ms

Before Lithium (for augmentation):

• U&Es, eGFR (renal function — lithium is nephrotoxic)
• TFTs (lithium causes hypothyroidism)
• ECG (affects cardiac conduction)
• Pregnancy test if applicable (lithium is teratogenic)
• Lithium levels monitored 12 hours post-dose (target 0.6-1.0 mmol/L)

Functional and Severity Assessment

Functional Impairment:

• Work absence or productivity
• Social withdrawal
• Self-care and activities of daily living
• Relationship quality

Suicide Risk Assessment (documented at every contact):

• Ideation, plan, intent, means, protective factors
• Use Columbia Suicide Severity Rating Scale (C-SSRS) if available

---

6. Management

Management of Major Depressive Disorder follows a stepped-care model (NICE guidelines) matched to severity, with the goal of achieving full remission (not just response) to prevent chronicity and recurrence. [24] Treatment combines pharmacotherapy, psychotherapy, and psychosocial interventions tailored to individual patient needs, preferences, and previous responses.

NICE Stepped Care Model

Pharmacological Treatment

First-Line: Selective Serotonin Reuptake Inhibitors (SSRIs)

SSRIs are first-line due to efficacy, tolerability, and safety profile. [4,8] All SSRIs are approximately equally effective; choice based on side effect profile, drug interactions, and patient factors.

SSRI Mechanism: Selective inhibition of serotonin reuptake transporter (SERT) → increased synaptic serotonin in raphe nuclei projections (prefrontal cortex, hippocampus, amygdala)

Time Course:

• Initial response: 2-4 weeks (some improvement may be seen by 2 weeks)
• Full therapeutic effect: 4-6 weeks
• If no response by 6 weeks at adequate dose, consider switch or augmentation

Common Side Effects:

• GI: nausea, diarrhea (usually transient, first 2 weeks)
• Sexual dysfunction: reduced libido, anorgasmia, erectile dysfunction (30-60%) — often persists
• Headache
• Insomnia or sedation (drug-dependent)
• Weight gain (long-term, variable)
• Hyponatraemia (especially elderly — monitor U&Es)

Serious Adverse Effects (Rare):

• Serotonin syndrome (with MAOIs, tramadol, triptans): agitation, hyperthermia, tremor, hyperreflexia, myoclonus
• QTc prolongation (citalopram, escitalopram): risk of Torsades de Pointes
• GI bleeding (especially with NSAIDs/antiplatelet agents): consider PPI co-prescription
• Increased suicide risk in less than 25 years in first weeks (controversial; monitor closely)

Second-Line Antidepressants

Tricyclic Antidepressants (TCAs)

Now third-line due to side effects and toxicity in overdose, but effective (especially melancholic depression).

Contraindications: Recent MI, heart block (2nd/3rd degree), arrhythmia, QTc >450ms, glaucoma, urinary retention
Side Effects: Antimuscarinic (dry mouth, constipation, urinary retention, blurred vision), sedation, weight gain, postural hypotension, arrhythmia, QTc prolongation
Overdose: Lethal — cardiac arrhythmia, seizures, coma; avoid if suicide risk

Monoamine Oxidase Inhibitors (MAOIs)

Specialist use only due to dietary restrictions and drug interactions.

• Phenelzine, Tranylcypromine: irreversible MAOIs
• Moclobemide: reversible MAOI-A (safer, fewer restrictions)

Indications: Treatment-resistant depression; atypical depression (historical indication)
Dietary Restrictions: Avoid tyramine-rich foods (aged cheese, cured meats, alcohol) → hypertensive crisis
Drug Interactions: Contraindicated with other antidepressants (serotonin syndrome), opioids, decongestants

Treatment Principles

Starting Treatment:

1. Monotherapy initially (single antidepressant)
2. Start low, go slow in elderly, medically ill, or first episode
3. Standard dose in uncomplicated adults (e.g., sertraline 50mg)
4. Psychoeducation: explain 4-6 week delay, side effects, importance of adherence
5. Follow-up: 1-2 weeks initially (suicide risk, side effects), then monthly

Monitoring Response:

• Use PHQ-9 at each visit to track symptom change
• Response defined as ≥50% reduction in symptom score
• Remission defined as PHQ-9 less than 5 or near-complete symptom resolution
• Goal is remission, not just response

If Inadequate Response at 4-6 Weeks:

1. Check adherence and adequacy of dose
2. Optimise dose (e.g., sertraline 50mg → 100mg → 150mg)
3. If no response after 6 weeks at adequate dose: switch or augment

Switching Strategies:

• Within SSRI class: direct switch at equivalent dose
• Between classes: consider washout period (especially to/from MAOIs — 2 weeks; 5 weeks from fluoxetine)
• Avoid abrupt discontinuation (withdrawal syndrome)

Continuation and Maintenance:

• Continue for 6-12 months after remission (first episode) to prevent relapse [10]
• ≥2 years if recurrent depression (≥2 previous episodes)
• Indefinite maintenance if ≥3 episodes, severe episodes, residual symptoms, or rapid relapse
• Taper slowly over 4 weeks when discontinuing (longer for paroxetine, venlafaxine)

Psychological Therapies

High-intensity psychological therapy is as effective as antidepressants for mild-moderate depression and should be offered as first-line option or in combination. [5,25]

Cognitive Behavioural Therapy (CBT)

Mechanism: Identify and modify negative automatic thoughts, cognitive distortions, and maladaptive behaviours

Structure: 12-20 sessions, weekly, 50-60 minutes

Evidence: Extensive RCT evidence; effective for acute treatment and relapse prevention; effects sustained post-therapy [25]

Components:

• Cognitive restructuring: identify cognitive distortions (catastrophising, overgeneralisation), challenge with evidence, develop balanced alternatives
• Behavioural activation: increase engagement in pleasurable and mastery activities
• Relapse prevention: identify early warning signs, develop coping strategies

Indications: Moderate-severe depression; patient preference; maintenance therapy to prevent relapse

Interpersonal Therapy (IPT)

Mechanism: Focus on interpersonal issues contributing to depression (grief, role disputes, role transitions, interpersonal deficits)

Structure: 12-16 sessions, weekly

Evidence: Equivalent efficacy to CBT in acute phase; effective for depression with clear interpersonal triggers [26]

Focus Areas:

• Complicated bereavement
• Role disputes (marital conflict, work relationships)
• Role transitions (retirement, illness, divorce)
• Interpersonal sensitivity

Behavioural Activation (BA)

Mechanism: Systematically increase engagement in rewarding activities to break cycle of inactivity → low mood → further inactivity

Structure: 8-16 sessions; simpler than full CBT

Evidence: Effective as CBT for depression; may be delivered by non-specialist practitioners [21]

Technique:

• Activity monitoring and scheduling
• Identify avoided activities
• Graded exposure to valued activities
• Problem-solving barriers

Other Psychological Approaches

Low-Intensity Interventions (Step 2)

For mild depression or patient preference:

• Guided self-help: CBT-based workbooks with brief therapist support
• Computerised CBT: online platforms (e.g., Beating the Blues, MoodGYM)
• Exercise programmes: aerobic exercise 3×/week equivalent to antidepressants for mild-moderate depression (smaller studies)
• Group-based peer support

Combination Therapy

Antidepressant + Psychotherapy is more effective than either alone for moderate-severe depression. [5]

NICE Recommendation:

• Mild depression: psychotherapy OR antidepressant (patient choice)
• Moderate depression: psychotherapy OR antidepressant OR combination (patient choice)
• Severe depression: antidepressant AND psychotherapy (combination recommended)

Advantages of Combination:

• Faster symptom improvement
• Higher remission rates
• Addresses biological and psychological factors
• Relapse prevention (psychological therapy provides skills)

Treatment-Resistant Depression (TRD)

Defined as failure to respond to ≥2 adequate trials of antidepressants (adequate dose for ≥4-6 weeks each, from different classes).

Affects ~30% of patients. [9]

Approach to TRD

1. Re-evaluate Diagnosis

• Is it truly MDD? (Consider bipolar disorder, personality disorder, substance use)
• Comorbid conditions? (anxiety, PTSD, substance use)
• Organic causes addressed? (hypothyroidism, anaemia)

2. Optimise Current Treatment

• Adequate dose?
• Adequate duration (≥6 weeks)?
• Adherence?
• Drug interactions?

3. Switch Antidepressant

• Switch class (e.g., SSRI → SNRI, SSRI → mirtazapine)
• Try TCA if not done (if medically safe)
• Consider MAOI (specialist only)

4. Augmentation Strategies

5. Electroconvulsive Therapy (ECT)

Gold standard for treatment-resistant depression. See dedicated section below.

6. Novel/Experimental Treatments

Electroconvulsive Therapy (ECT)

ECT is the most effective treatment for severe depression, with response rates of 70-90%. [30] It is underutilised due to stigma but is safe and life-saving.

Indications:

• Severe depression with:
  • Life-threatening features (severe self-neglect, dehydration, refusal to eat/drink)
  • High suicide risk requiring rapid response
  • Catatonia or stupor
• Psychotic depression (equivalent to antipsychotic + antidepressant)
• Treatment-resistant depression (failed ≥2 antidepressant trials)
• Patient preference (e.g., rapid response needed, previous response to ECT)

Mechanism: Induced generalised seizure under general anaesthesia → unclear mechanism; theories include neurotransmitter changes, neuroplasticity, HPA axis normalisation

Procedure:

• General anaesthesia + muscle relaxant (succinylcholine)
• Brief electrical stimulus via scalp electrodes → seizure (20-60 seconds)
• Bilateral (more effective, more cognitive side effects) or unilateral (right-sided, fewer cognitive effects)
• Course: 6-12 treatments over 2-4 weeks (2-3×/week)

Efficacy:

• Response rate: 70-80% in severe depression [30]
• 90% in psychotic depression
• 50-60% in treatment-resistant depression
• Effect seen after 2-4 treatments; maximum effect after full course

Side Effects:

• Transient confusion immediately post-treatment (minutes to hours)
• Anterograde amnesia (difficulty forming new memories during treatment course) — resolves
• Retrograde amnesia (memory loss for period around treatment) — usually resolves within 6 months; rarely persistent
• Headache, muscle aches
• Cardiovascular: transient tachycardia, hypertension during procedure

Contraindications (relative — risk-benefit assessment):

• Raised intracranial pressure (brain tumour, recent stroke)
• Recent MI (less than 3 months)
• Unstable cardiovascular disease
• Severe anaesthetic risk

Post-ECT Management:

• Continue/start antidepressant to prevent relapse (50% relapse within 6 months without maintenance treatment)
• Consider maintenance ECT (monthly) if recurrent relapses

Physical Treatments and Lifestyle Interventions

Exercise:

• Aerobic exercise (30 min, 3-5×/week) has antidepressant effects equivalent to medication in mild-moderate depression (meta-analysis) [31]
• Mechanisms: endorphins, neuroplasticity (BDNF), HPA axis normalisation, social engagement
• Recommend as adjunct to all patients

Sleep Hygiene:

• Regular sleep-wake times
• Avoid caffeine, alcohol, screens before bed
• Address insomnia (CBT for insomnia if persistent)

Light Therapy:

• 10,000 lux light box for 30 minutes daily (morning)
• Evidence for seasonal affective disorder (winter depression) [32]
• Emerging evidence for non-seasonal depression

Dietary Interventions:

• Mediterranean diet associated with reduced depression risk
• Omega-3 supplementation: weak evidence
• Folate, vitamin D supplementation if deficient

Social Prescribing:

• Volunteering, group activities, structured day programmes
• Address isolation, unemployment, housing

Special Populations

Pregnancy and Breastfeeding

Risk-Benefit Assessment: Untreated depression in pregnancy has risks (poor self-care, preterm birth, low birth weight, postpartum depression)

Psychological Therapy: First-line in pregnancy if mild-moderate

Antidepressants in Pregnancy:

• SSRIs generally safe (sertraline, fluoxetine preferred)
• Avoid paroxetine (cardiac malformations), venlafaxine in 3rd trimester
• Continue if previously stable on antidepressant (relapse risk if stopped)
• Inform neonatology if on SSRI in 3rd trimester (neonatal adaptation syndrome: jitteriness, feeding difficulty — transient)

Breastfeeding: SSRIs compatible; sertraline lowest levels in breast milk

ECT: Safe in pregnancy (all trimesters) if severe/life-threatening depression

Elderly (>65 years)

• Start antidepressants at half-dose (increased sensitivity, comorbidities)
• Citalopram max 20mg (QTc prolongation)
• Monitor for hyponatraemia (SIADH risk with SSRIs)
• Avoid TCAs (falls, cognitive impairment, cardiac risk)
• "Pseudodementia" (cognitive impairment in depression) improves with treatment
• Higher suicide risk in elderly men

Children and Adolescents (less than 18 years)

• Psychological therapy first-line (CBT, family therapy)
• Fluoxetine is only SSRI licensed for depression in children (age 8+)
• Increased suicide risk with SSRIs in less than 25 years (controversial) — close monitoring essential
• Involve family

Comorbid Medical Illness

• Post-MI: sertraline safe and reduces cardiovascular mortality [33]
• Diabetes: duloxetine useful (diabetic neuropathy); improve glycaemic control by treating depression
• Chronic pain: duloxetine, amitriptyline (dual benefit)
• Parkinson's disease: avoid antipsychotics (worsen motor symptoms); SSRIs safe
• Epilepsy: avoid bupropion (lowers seizure threshold); SSRIs/SNRIs safe

---

7. Complications

Acute Complications

Chronic Complications

Recurrence and Chronicity:

• 50% recurrence after first episode [3]
• 80% recurrence after two episodes
• 90% recurrence after three episodes
• Each episode increases risk of subsequent episodes and reduces likelihood of full recovery
• Chronic depression (≥2 years) in 20-30% without adequate treatment

Treatment-Resistant Depression:

• 30% fail to respond to ≥2 antidepressant trials [9]
• Requires specialist input, augmentation, ECT

Functional Impairment:

• Work disability: leading cause of sick leave and disability pension
• Relationship breakdown: 50% higher divorce rate
• Social isolation: withdrawal, loss of friendships
• Cognitive impairment: "pseudodementia" (reversible); true cognitive decline if chronic

Physical Health Consequences:

• Cardiovascular disease: 2-3× risk of MI, stroke [11]
  • "Mechanisms: inflammation, platelet activation, HPA axis dysregulation, health behaviours"
  • Depression post-MI increases mortality 2-3×
• Diabetes: bidirectional relationship; depression worsens glycaemic control
• Chronic pain syndromes: comorbidity in 50-75%
• Obesity: weight gain from reduced activity, comfort eating, medication
• Reduced life expectancy: 10-20 years (suicide, cardiovascular disease, cancer, accidents)

Substance Use Disorders:

• Comorbid in 30% of MDD [34]
• Alcohol use disorder (self-medication)
• Cannabis, benzodiazepines, opioids
• Worse outcomes; requires integrated treatment

Impact on Others:

• Children of depressed parents: 2-3× risk of depression, behavioural problems, academic difficulties
• Caregivers: burden, stress, own mental health problems

---

8. Prognosis

Natural History

Untreated Episode:

• Duration: 6-12 months (median 9 months)
• 20% still depressed at 2 years
• Longer duration predicts worse long-term outcome

With Treatment:

• 60-70% remission within 6 months with first antidepressant [8]
• 33% remission with first SSRI in STAR*D trial; cumulative 67% over 4 sequential steps [9]
• Combination therapy (antidepressant + psychotherapy) achieves higher remission rates than either alone [5]

Recurrence:

• 50% after first episode [3]
• 80% after two episodes
• 90% after three episodes
• Continuation therapy (6-12 months) reduces relapse by 70% [10]
• Maintenance therapy (≥2 years) recommended if ≥2 previous episodes

Prognostic Factors

Poor Prognosis (Predictors of Chronicity and Recurrence):

Good Prognosis (Predictors of Recovery):

Long-Term Outcomes

Recovery Rates (longitudinal studies):

• 50% full recovery after first episode (never recur)
• 20-30% partial recovery (residual symptoms, functional impairment)
• 20% chronic course (persistent symptoms ≥2 years)

Suicide:

• Lifetime risk: 4% in community samples; 15-20% in severe/hospitalised depression [7]
• Highest risk: first months of treatment (energy improves before mood), discontinuation of treatment, recent discharge from hospital
• Older men highest risk group

Functional Recovery:

• Lags behind symptom recovery
• 50% have persistent occupational impairment despite symptom remission
• Cognitive impairment may persist in chronic/recurrent cases

---

9. Prevention and Relapse Prevention

Primary Prevention

Population Level:

• Public mental health campaigns (reducing stigma, promoting help-seeking)
• Stress reduction, work-life balance initiatives
• Social determinants: poverty reduction, employment programmes, housing
• Exercise and healthy lifestyle promotion

Individual Level (High-Risk Groups):

• Adverse childhood experiences: trauma-focused therapy, family support
• Family history: psychoeducation, early symptom recognition
• Post-partum: screening (Edinburgh Postnatal Depression Scale), preventative psychological therapy
• Medical illness: integrated care, routine screening (especially post-MI, diabetes, stroke)

Secondary Prevention (Relapse Prevention)

Continuation Therapy (after acute remission):

• Continue antidepressant 6-12 months after first episode [10]
• Continue ≥2 years after second episode
• Consider indefinite maintenance if ≥3 episodes, severe episodes, rapid relapse, or residual symptoms

Dose:

• Same dose that achieved remission (do not reduce)

Psychological Therapy for Relapse Prevention:

• Mindfulness-Based Cognitive Therapy (MBCT): 8-week group programme; reduces relapse by 40-50% in recurrent depression (≥3 episodes) [27]
• Continuation CBT: booster sessions (monthly) reduce relapse

Self-Management:

• Relapse signature recognition: early warning signs (sleep disturbance, withdrawal, negative thinking)
• Action plan: steps to take if early symptoms emerge (contact clinician, restart therapy, increase support)
• Lifestyle: maintain exercise, sleep hygiene, social connection
• Avoid triggers: excessive stress, substance use

Monitoring and Follow-Up

• Regular follow-up during continuation phase (3-monthly minimum)
• PHQ-9 monitoring for early symptom detection
• Medication adherence support
• Address life stressors proactively

---

10. Key Guidelines and Evidence Base

Major Clinical Guidelines

Landmark Trials and Evidence

STAR*D (Sequenced Treatment Alternatives to Relieve Depression) [9]

• Largest pragmatic trial (n=4,041) of treatment-resistant depression
• 33% remission with first SSRI (citalopram)
• Cumulative 67% remission over 4 sequential steps (switch/augment strategies)
• Demonstrates need for multiple treatment attempts

COMBINE Studies [5]

• Meta-analyses showing combination therapy (antidepressant + psychotherapy) superior to either alone
• Particularly effective in severe depression

ECT Meta-Analyses [30]

• Response rate 70-80% in severe depression
• Most effective treatment available
• Superior to medication in severe/psychotic depression

NICE Meta-Analyses of Antidepressants [24]

• SSRIs, SNRIs, mirtazapine, TCAs all effective
• Sertraline/escitalopram best efficacy-tolerability balance
• All superior to placebo (SMD ~0.3)

Exercise Meta-Analyses [31]

• Aerobic exercise equivalent to antidepressants in mild-moderate depression
• Effect size moderate (SMD ~0.4-0.6)

MBCT Trials [27]

• 40-50% relapse reduction in recurrent depression (≥3 episodes)
• Non-inferior to maintenance antidepressants

---

11. Exam-Focused Content

Common Viva Questions

Q1: "What is Major Depressive Disorder?"

Model Answer: "Major Depressive Disorder is a common and serious mood disorder characterised by persistent low mood, anhedonia, and associated cognitive, behavioural, and somatic symptoms lasting at least 2 weeks with functional impairment. It affects 5-7% of adults at any time, with a 2:1 female predominance. Diagnosis is clinical, based on DSM-5 criteria requiring ≥5 symptoms including at least one core symptom (low mood or anhedonia). Treatment involves a biopsychosocial approach: antidepressants (SSRIs first-line), psychological therapy (CBT, IPT), and addressing social factors. Early recognition and treatment significantly improve outcomes, with 60-70% responding to first-line treatment."

Q2: "How would you assess suicide risk in a depressed patient?"

Model Answer: "Suicide risk assessment is mandatory at every contact with a depressed patient. I would ask directly about suicidal thoughts, plans, intent, and access to means, as direct questioning does not increase risk. Key risk factors include previous suicide attempts (strongest predictor), current ideation with specific plans and intent, male sex, older age, social isolation, comorbid substance use, hopelessness, and recent loss. Protective factors include social support, dependent children, and religious beliefs. I would use the SAD PERSONS mnemonic to systematically assess risk. High-risk patients with intent, plan, means, and no protective factors require psychiatric emergency assessment and likely admission. All patients should have a safety plan and crisis contacts documented."

Q3: "What is your approach to treatment-resistant depression?"

Model Answer: "Treatment-resistant depression is defined as failure to respond to at least two adequate trials of antidepressants from different classes, each at therapeutic dose for ≥4-6 weeks. It affects approximately 30% of patients. My approach would be systematic: first, re-evaluate the diagnosis to exclude bipolar disorder, comorbid conditions, or organic causes; second, ensure adherence and adequate treatment optimisation; third, consider switching antidepressant class; fourth, try augmentation strategies, with lithium having the strongest evidence, followed by aripiprazole; fifth, consider combination antidepressants; and finally, for severe or refractory cases, electroconvulsive therapy, which has 70-80% response rates and is the most effective treatment available. Novel approaches like ketamine may be considered in specialist centres."

Q4: "Compare SSRIs and SNRIs."

High-Yield Facts for Examinations

"Rule of 2s" in Depression:

• 2:1 female:male ratio
• 2 weeks minimum duration for diagnosis
• 2-4 weeks for initial SSRI response
• 2 adequate trials define treatment-resistant depression
• 2× risk of MI with comorbid depression
• ≥2 previous episodes require ≥2 years maintenance therapy

PHQ-9 Thresholds (memorise):

• 5-9: Mild
• 10-14: Moderate
• 15-19: Moderately severe
• ≥20: Severe

SSRI Pearls:

• Sertraline: NICE first choice, safe post-MI
• Fluoxetine: long half-life (7 days), less withdrawal, only SSRI for children
• Citalopram: QTc prolongation, max 20mg if >65 years
• Paroxetine: worst withdrawal, avoid

ECT Facts:

• 70-80% response in severe depression
• 90% in psychotic depression
• Bilateral > unilateral for efficacy (but more cognitive effects)
• Side effect: retrograde amnesia (usually resolves)
• Contraindication: raised ICP

Common Mistakes to Avoid

❌ Failing to assess suicide risk directly — always ask explicitly
❌ Diagnosing MDD without checking duration (must be ≥2 weeks)
❌ Starting antidepressant without baseline investigations (TFTs, FBC, U&Es)
❌ Stopping antidepressant too soon (continue 6-12 months after remission)
❌ Not warning about delayed onset of SSRIs (4-6 weeks) — leads to non-adherence
❌ Missing organic causes (hypothyroidism, anaemia, medication-induced)
❌ Diagnosing MDD in presence of manic episodes (it's bipolar disorder)
❌ Assuming all depression is the same (melancholic, atypical, psychotic subtypes differ)

---

12. Patient/Layperson Explanation

What is Depression?

Depression is more than just feeling sad. It's a medical illness that affects how you think, feel, and function in daily life. Just like diabetes affects blood sugar or asthma affects breathing, depression affects brain chemistry and mood regulation. It's very common — about 1 in 5 people will experience it in their lifetime — and it's not a sign of weakness or something you can "snap out of."

The main features are:

• Persistent low mood: feeling sad, empty, or hopeless most of the time for at least 2 weeks
• Loss of interest and pleasure: not enjoying things you used to love (hobbies, time with friends, activities)
• Low energy: everything feels exhausting, even small tasks

Other symptoms can include sleep problems, appetite changes, difficulty concentrating, feelings of worthlessness, and in severe cases, thoughts of suicide.

What Causes Depression?

Depression doesn't have a single cause — it's a combination of factors:

Brain Chemistry: Imbalances in mood-regulating chemicals (serotonin, norepinephrine) in the brain

Genetics: Depression runs in families — if a parent or sibling has depression, your risk is 2-3 times higher

Life Events: Stressful events like bereavement, relationship breakdown, job loss, or trauma can trigger depression

Medical Illness: Chronic conditions like heart disease, diabetes, or thyroid problems can cause or worsen depression

Lifestyle: Social isolation, lack of exercise, poor sleep, and substance use increase risk

How is Depression Treated?

The good news is that depression is highly treatable. About 7 in 10 people improve with treatment.

Talking Therapies (Psychotherapy):

• Cognitive Behavioural Therapy (CBT): helps identify and change negative thought patterns
• Interpersonal Therapy (IPT): focuses on relationships and life changes
• Usually 12-16 weekly sessions
• As effective as medication for mild-moderate depression

Antidepressant Medication:

• Most people start with an SSRI (e.g., sertraline, fluoxetine, citalopram)
• Not addictive or "happy pills" — they correct chemical imbalances
• Take 4-6 weeks to work — it's important to keep taking them even if you don't feel better immediately
• Side effects (nausea, headache) usually improve after 1-2 weeks
• Continue for 6-12 months after feeling better to prevent relapse

Combination:

• Medication plus therapy works better than either alone for moderate-severe depression

Lifestyle:

• Exercise: 30 minutes of activity 3-5 times a week is as effective as medication for mild depression
• Sleep routine: regular sleep-wake times
• Social connection: staying connected even when you don't feel like it
• Avoid alcohol: worsens depression and interferes with treatment

Other Treatments (for severe cases):

• Electroconvulsive Therapy (ECT): very effective (7-8 in 10 improve) for severe depression; modern ECT is safe under anaesthetic; causes temporary memory problems

When to Seek Urgent Help

Go to A&E or call 999 if you or someone else:

• Has thoughts of suicide or self-harm
• Has made a plan to end their life
• Feels unable to keep themselves safe
• Has harmed themselves

Helplines (UK):

• Samaritans: 116 123 (free, 24/7)
• Crisis Text Line: Text SHOUT to 85258
• Papyrus (under 35): 0800 068 4141

What to Expect

• Recovery is possible — most people improve within 2-3 months with treatment
• It's not your fault — depression is a medical illness, not a personal failure
• Treatment works — don't give up if the first treatment doesn't help; there are many options
• Involve your GP — they can refer you for therapy, prescribe medication, and monitor progress
• Tell someone you trust — isolation makes depression worse; support helps

---

13. References

1. Kennedy SH, Lam RW, McIntyre RS, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 Update on Clinical Guidelines for Management of Major Depressive Disorder in Adults. Can J Psychiatry. 2024;69(9):641-687. doi:10.1177/07067437241245384

2. Hasin DS, Sarvet AL, Meyers JL, et al. Epidemiology of Adult DSM-5 Major Depressive Disorder and Its Specifiers in the United States. JAMA Psychiatry. 2018;75(4):336-346. doi:10.1001/jamapsychiatry.2017.4602

3. Hardeveld F, Spijker J, De Graaf R, et al. Recurrence of major depressive disorder and its predictors in the general population: results from The Netherlands Mental Health Survey and Incidence Study (NEMESIS). Psychol Med. 2013;43(1):39-48. doi:10.1017/S0033291712002395

4. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018;391(10128):1357-1366. doi:10.1016/S0140-6736(17)32802-7

5. Cuijpers P, Dekker J, Hollon SD, Andersson G. Adding psychotherapy to pharmacotherapy in the treatment of depressive disorders in adults: a meta-analysis. J Clin Psychiatry. 2009;70(9):1219-1229. doi:10.4088/JCP.09r05021

6. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289(23):3095-3105. doi:10.1001/jama.289.23.3095

7. Chesney E, Goodwin GM, Fazel S. Risks of all-cause and suicide mortality in mental disorders: a meta-review. World Psychiatry. 2014;13(2):153-160. doi:10.1002/wps.20128

8. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163(1):28-40. doi:10.1176/appi.ajp.163.1.28

9. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905-1917. doi:10.1176/ajp.2006.163.11.1905

10. Geddes JR, Carney SM, Davies C, et al. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet. 2003;361(9358):653-661. doi:10.1016/S0140-6736(03)12599-8

11. Frasure-Smith N, Lespérance F. Depression and cardiac risk: present status and future directions. Heart. 2010;96(3):173-176. doi:10.1136/hrt.2009.186957

12. Mitchell AJ, Vaze A, Rao S. Clinical diagnosis of depression in primary care: a meta-analysis. Lancet. 2009;374(9690):609-619. doi:10.1016/S0140-6736(09)60879-5

13. Sullivan PF, Neale MC, Kendler KS. Genetic epidemiology of major depression: review and meta-analysis. Am J Psychiatry. 2000;157(10):1552-1562. doi:10.1176/appi.ajp.157.10.1552

14. Nanni V, Uher R, Danese A. Childhood maltreatment predicts unfavorable course of illness and treatment outcome in depression: a meta-analysis. Am J Psychiatry. 2012;169(2):141-151. doi:10.1176/appi.ajp.2011.11020335

15. Gavin NI, Gaynes BN, Lohr KN, et al. Perinatal depression: a systematic review of prevalence and incidence. Obstet Gynecol. 2005;106(5 Pt 1):1071-1083. doi:10.1097/01.AOG.0000183597.31630.db

16. Pariante CM, Lightman SL. The HPA axis in major depression: classical theories and new developments. Trends Neurosci. 2008;31(9):464-468. doi:10.1016/j.tins.2008.06.006

17. Duman RS, Aghajanian GK. Synaptic dysfunction in depression: potential therapeutic targets. Science. 2012;338(6103):68-72. doi:10.1126/science.1222939

18. Köhler-Forsberg O, Lydholm CN, Hjorthøj C, et al. Efficacy of anti-inflammatory treatment on major depressive disorder or depressive symptoms: meta-analysis of clinical trials. Acta Psychiatr Scand. 2019;139(5):404-419. doi:10.1111/acps.13016

19. Beck AT. The evolution of the cognitive model of depression and its neurobiological correlates. Am J Psychiatry. 2008;165(8):969-977. doi:10.1176/appi.ajp.2008.08050721

20. Seligman ME. Learned helplessness. Annu Rev Med. 1972;23:407-412. doi:10.1146/annurev.me.23.020172.002203

21. Dimidjian S, Hollon SD, Dobson KS, et al. Randomized trial of behavioral activation, cognitive therapy, and antidepressant medication in the acute treatment of adults with major depression. J Consult Clin Psychol. 2006;74(4):658-670. doi:10.1037/0022-006X.74.4.658

22. Ghaziuddin M, King CA, Hovey JD, et al. Melancholic depression in children and adolescents. J Affect Disord. 1996;38(1):23-28. doi:10.1016/0165-0327(95)00089-5

23. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606-613. doi:10.1046/j.1525-1497.2001.016009606.x

24. National Institute for Health and Care Excellence. Depression in adults: treatment and management. NICE guideline [NG222]. Published June 2022. Updated June 2023. https://www.nice.org.uk/guidance/ng222

25. Hofmann SG, Asnaani A, Vonk IJ, et al. The efficacy of cognitive behavioral therapy: a review of meta-analyses. Cognit Ther Res. 2012;36(5):427-440. doi:10.1007/s10608-012-9476-1

26. Cuijpers P, Geraedts AS, van Oppen P, et al. Interpersonal psychotherapy for depression: a meta-analysis. Am J Psychiatry. 2011;168(6):581-592. doi:10.1176/appi.ajp.2010.10101411

27. Kuyken W, Warren FC, Taylor RS, et al. Efficacy of Mindfulness-Based Cognitive Therapy in Prevention of Depressive Relapse: An Individual Patient Data Meta-analysis From Randomized Trials. JAMA Psychiatry. 2016;73(6):565-574. doi:10.1001/jamapsychiatry.2016.0076

28. Bauer M, Adli M, Ricken R, et al. Role of lithium augmentation in the management of major depressive disorder. CNS Drugs. 2014;28(4):331-342. doi:10.1007/s40263-014-0152-8

29. McIntyre RS, Rosenblat JD, Nemeroff CB, et al. Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation. Am J Psychiatry. 2021;178(5):383-399. doi:10.1176/appi.ajp.2020.20081251

30. UK ECT Review Group. Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet. 2003;361(9360):799-808. doi:10.1016/S0140-6736(03)12705-5

31. Schuch FB, Vancampfort D, Richards J, et al. Exercise as a treatment for depression: A meta-analysis adjusting for publication bias. J Psychiatr Res. 2016;77:42-51. doi:10.1016/j.jpsychires.2016.02.023

32. Golden RN, Gaynes BN, Ekstrom RD, et al. The efficacy of light therapy in the treatment of mood disorders: a review and meta-analysis of the evidence. Am J Psychiatry. 2005;162(4):656-662. doi:10.1176/appi.ajp.162.4.656

33. Berkman LF, Blumenthal J, Burg M, et al. Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) Randomized Trial. JAMA. 2003;289(23):3106-3116. doi:10.1001/jama.289.23.3106

34. Grant BF, Stinson FS, Dawson DA, et al. Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry. 2004;61(8):807-816. doi:10.1001/archpsyc.61.8.807

35. Gelenberg AJ, Freeman MP, Markowitz JC, et al. American Psychiatric Association Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition. Am J Psychiatry. 2010;167(10):1-152. https://psychiatryonline.org/guidelines

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. It does not replace professional medical judgement. Always verify critical information, consider individual patient factors, and consult current guidelines. Suicide risk assessment and management of severe depression require clinical expertise and should not be based solely on written resources.